

Contains Nonbinding Recommendations

Draft Guidance on Tipranavir

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Tipranavir

Form/Route: Capsules/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover *in-vivo*
Strength: 250 mg (please administer a 500 mg dose; 2 X 250 mg)
Subjects: Normal healthy males and females, general population.
Additional Comments: Females must have a negative baseline pregnancy test within 24 hours prior to receiving the drug. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

2. Type of study: Fed
Design: Single-dose, two-treatment, two-period crossover *in-vivo*
Strength: 250 mg (please administer a 500 mg dose; 2 X 250 mg)
Subjects: Normal healthy males and females, general population.
Additional comments: Please see comment above.

Analytes to measure (in appropriate biological fluid): Tipranavir in plasma

Bioequivalence based on (90% CI): Tipranavir

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.